Akero Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing transformational treatments for non-alcoholic steatohepatitis and other serious metabolic disorders. The company's product pipeline consists of AKR-001, for the treatment of non-alcoholic steatohepatitis, which are in clinical stage. Akero Therapeutics Inc. is based in San Francisco, United States.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-151.76M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.30 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -29.59% |
| Return on Assets (Trailing 12 Months) | -27.10% |
| Current Ratio (Most Recent Fiscal Quarter) | 29.27 |
| Quick Ratio (Most Recent Fiscal Quarter) | 29.27 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.05 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.61 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.99 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.89 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.85 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 69.15M |
| Free Float | 62.45M |
| Market Capitalization | $1.53B |
| Average Volume (Last 20 Days) | 0.72M |
| Beta (Past 60 Months) | -0.29 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.69% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |